News
People with hepatitis C who sought prescriptions for highly effective but pricey new drugs were significantly more likely to get turned down if they had Medicaid coverage than if they were insured by Medicare or private commercial policies, a recent study found.
A new report by The Commonwealth Fund has found that a quarter of working-age adults struggle to pay for their healthcare in 2015 in the wake of rising deductibles and out-of-pocket costs.
The Centers for Medicare and Medicaid Services is asking healthcare providers for information to aid in the design of a new survey of patient experience in long-term care hospitals.
Many primary care practitioners will be a little poorer next year because of the expiration of a health law program that has been paying them a 10 percent bonus for caring for Medicare patients.
In the last five years, 57 rural hospitals in the United States have closed, according to data from the Rural Health Research Program at the University of North Carolina. Others have declared bankruptcy, like the Mendocino Coast District Hospital.
A new report by The Commonwealth Fund has found that a quarter of working-age adults struggle to pay for their healthcare in 2015 in the wake of rising deductibles and out-of-pocket costs.
Acquisition represents a strategic fit for Bard as it enhances its position in the home care market.
As beneficiaries explore options during the current Medicare enrollment period, there are only 227 such plans from which they can choose next year, 20 percent fewer than this year, and the lowest number since the drug benefit was added to Medicare in 2006, according to the Centers for Medicare & Medicaid Services.
Vizient Inc., which becomes official on Jan. 1, 2016, will provide services to close to 30 percent of U.S. hospitals, including nearly all academic medical centers and health systems
Pharmaceutical giant Pfizer on Sunday said it would merge with Botox maker Allergan in a $160 billion deal that would shift the company's executive offices to Ireland in a tax-saving "inversion" deal that is sure to come under heavy regulatory scrutiny.